Wednesday, July 6, 2022 New Coronavirus Vaccine Study Shows Potential for 'Mosaic' Design Caption: This scanning electron microscope image shows SARS-CoV-2 (round gold objects) emerging from the surface of cells cultured in the lab. (NIAID)   NIAID scientists and colleagues have developed a promising pan-coronavirus vaccine, according to a new study in Science. The candidate vaccine – called mosaic-8 – combines parts of eight different sarbecoviruses and generates a protective antibody response in mice and monkeys. The sarbecovirus subgenus includes coronaviruses such as SARS-CoV and SARS-CoV-2. In the study, mosaic-8 protected mice and monkeys against SARS-CoV-2 and SARS-CoV, which was not included in the vaccine. The scientists believe this type of vaccine design could protect against a target virus – like SARS-CoV-2 – as well as its variants and other related emerging coronaviruses. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107